Even with such a bias potentially favoring those who were randomly assigned to continue with polypharmacy, the stay and switch groups did not differ with respect to symptom control, and switching to monotherapy resulted in weight loss (1) and, as noted here, a lower total antipsychotic load for most patients. All else being equal, exposing people to the adverse effects of fewer medications is preferable. The study results suggest that a trial with monotherapy can be considered by physicians and patients stable on antipsychotic polypharmacy with little concern about clinical status. We agree with Dr. Baandrup that increasing the dosage of the monotherapy is an important option to consider before going back to polypharmacy; however, many individuals did well without increasing the dosage of the remaining antipsychotic. We would be wary of a uniform strategy of increasing the dosage of the remaining antipsychotic when switching from antipsychotic polypharmacy to antipsychotic monotherapy.